Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

BACKGROUND: Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated with rituximab. However, the incidence and severity of breakthrough infections in unbiased samples of patients with specific rheumatic and musculoskele...

Descripción completa

Detalles Bibliográficos
Autores principales: Md Yusof, Md Yuzaiful, Arnold, Jack, Saleem, Benazir, Vandevelde, Claire, Dass, Shouvik, Savic, Sinisa, Vital, Edward M, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873269/
https://www.ncbi.nlm.nih.gov/pubmed/36712951
http://dx.doi.org/10.1016/S2665-9913(23)00004-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873269/
https://www.ncbi.nlm.nih.gov/pubmed/36712951
http://dx.doi.org/10.1016/S2665-9913(23)00004-8

Ejemplares similares